Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696085 · ClinicalTrials.gov registry record · NA
Fetal Alcohol Damage Prevention Study
A NA study of Substance Abuse and Fetal Alcohol Syndrome, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 612
- Enrollment target
- 1
- Study location
NCT00696085: Completed NA study of Substance Abuse and Fetal Alcohol Syndrome, sponsored by Massachusetts General Hospital.
NCT00696085 is a NA study of Substance Abuse and Fetal Alcohol Syndrome that has completed, run by Massachusetts General Hospital. The registered enrollment target is 612 participants, below the 5,249-participant average among 58 other Substance Abuse trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00696085, a NA study of Substance Abuse and Fetal Alcohol Syndrome, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 612 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study was to determine whether a series of blood markers of alcohol use obtained from alcohol using pregnant women could help them to change their behavior.
Conditions Studied
Interventions
- BEHAVIORAL Brief motivational intervention
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 612 participants |
| Start Date | 2004-03 |
| Est. Completion | 2008-02 |
| Phase | NA |
What the finished NCT00696085 record still lists
NCT00696085 is an interventional study that assigns participants to a tested intervention. The registered 612 participants enrollment target is mid-sized for trials with a published cap, below the 5,249-participant average among 58 other Substance Abuse trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Substance Abuse appearing as the primary indexed condition, and to 1 intervention - of which Brief motivational intervention is the first listed.
NCT00696085 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00696085 about?
NCT00696085 is a clinical study titled "Fetal Alcohol Damage Prevention Study". The goal of this study was to determine whether a series of blood markers of alcohol use obtained from alcohol using pregnant women could help them to change their behavior.
What is the current status of trial NCT00696085?
This trial is currently completed. It is a NA study. The enrollment target is 612 participants. The study started on 2004-03. Estimated completion is 2008-02.
What conditions does trial NCT00696085 study?
This clinical trial studies the following conditions: Substance Abuse, Fetal Alcohol Syndrome.
What interventions are being tested in trial NCT00696085?
The interventions under investigation include: Brief motivational intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT00696085?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00696085 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00696085's enrollment target sits among peer trials
612 9th of 58 higher than 50 of 58 other Substance Abuse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
RECRUITING · NA
-
Testing ALERT With GTO in Middle Schools
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
-
The STop UNhealthy Substance Use Now Trial
RECRUITING · NA
-
The Trans-Led Care Study
RECRUITING · NA
-
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04224493 · 612 participants · Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
- NCT04590326 · 612 participants · Phase 1
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- NCT06266416 · 612 participants · NA
IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)
- NCT01810913 · 613 participants · Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia